Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CriPec docetaxel in solid tumours
NCT02442531Phase 1Completed
- Sponsor
- Cristal Therapeutics
- Start
- Aug 2015
- Primary completion
- Jul 2018
- Modality
- Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of docetaxel in solid tumor, sponsored by Cristal Therapeutics. Primary endpoints: Incidence of grade 3 or 4 adverse events at 9 months, Incidence of clinical laboratory abnormalities at 9 months and 2 more. Started Aug 2015; status: completed.
02
Drugs
docetaxel
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02442531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02442531.